Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance
| Autor: | Aleksandra Opalska, Arjon J. van Hengel, Joseph Larsen, John-Arne Røttingen, Christine Årdal |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Motivation Public economics Drug Industry Task force business.industry 030106 microbiology Advisory Committees Anti-Bacterial Agents 03 medical and health sciences 0302 clinical medicine Infectious Diseases Incentive Work (electrical) Push and pull Drug Discovery Drug Resistance Bacterial Revenue Medicine Humans 030212 general & internal medicine Antibacterial drug business |
| Zdroj: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 65(8) |
| ISSN: | 1537-6591 |
| Popis: | New alternative market models are needed to incentivize companies to invest in developing new antibacterial drugs. In a previous publication, the Transatlantic Task Force on Antimicrobial Resistance (TATFAR) summarized the key areas of consensus for economic incentives for antibacterial drug development. That work determined that there was substantial agreement on the need for a mixture of push and pull incentives and particularly those that served to delink the revenues from the volumes sold. Pull incentives reward successful development by increasing or ensuring future revenue. Several pull incentives have been proposed that could substantially reward the development of new antibacterial drugs. In this second article authored by representatives of TATFAR, we examine the advantages and disadvantages of different pull incentives for antibacterial drug development. It is TATFAR's hope that this analysis, combined with other related analyses, will provide actionable information that will shape policy makers' thinking on this important issue. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|